Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Eisai Co., Ltd. clinical trials
The registry lists 644 studies whose lead sponsor is Eisai Co., Ltd. or one of 7 companies grouped under it. 16 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Eisai Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Eisai Co., Ltd..
- Eisai Inc.368 studiesSame company
Something wrong?
- Eisai Co., Ltd.152 studiesSame company
Something wrong?
- Eisai Limited48 studiesSame company
Something wrong?
- Eisai Korea Inc.31 studies →Regional office
Something wrong?
- Morphotek21 studies →Acquired
Something wrong?
- EA Pharma Co., Ltd.13 studies →Acquired
Something wrong?
- Eisai GmbH4 studiesSame company
Something wrong?
- Eisai Pharmaceuticals India Pvt. Ltd3 studies →Regional office
Something wrong?
- Eisai China Inc.2 studies →Regional office
Something wrong?
- Eisai Farmacêutica S.A.1 study →Regional office
Something wrong?
- H3 Biomedicine Inc.1 study →Subsidiary
Something wrong?
Focus areas
Conditions Eisai Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 644. Browse all 644 →
- A Post Authorization Registry Study of Participants Treated With LEQEMBIRecruitingNCT07762092
Sponsor listed in the registry: Eisai Limited
- A Postmarketing Study of LEQEMBI in Participants With Alzheimer's DiseaseNot yet recruitingNCT07864623
Sponsor listed in the registry: Eisai Inc.
- A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy ParticipantsRecruitingNCT07766369Phase 1
Sponsor listed in the registry: Eisai Inc.
- Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy ParticipantsRecruitingNCT04271488Phase 1
- A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's DiseaseRecruitingNCT07821658
Sponsor listed in the registry: Eisai Inc.
- A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)Not yet recruitingNCT07781345
Sponsor listed in the registry: Eisai Limited
- A Study of E6742 in Participants With Systemic Lupus ErythematosusRecruitingNCT07515014Phase 2
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)Not yet recruitingNCT07768592Phase 1
Sponsor listed in the registry: Eisai Inc.
- An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303AvailableNCT03778424
Sponsor listed in the registry: Eisai Inc.
- A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean ParticipantsRecruitingNCT06246123
Sponsor listed in the registry: Eisai Korea Inc.
- A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic SeizuresRecruitingNCT06657378
- A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesRecruitingNCT04300556Phase 1/2
Sponsor listed in the registry: Eisai Inc.
- A Study to Evaluate the Efficacy and Safety of E2086 in Adults With NarcolepsyRecruitingNCT07493265Phase 2
Sponsor listed in the registry: Eisai Inc.
- A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's DiseaseRecruitingNCT06810960
Sponsor listed in the registry: Eisai Korea Inc.
- A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyRecruitingNCT06793709
- A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With LecanemabRecruitingNCT06322667
- A Study of E7130 in Participants With Solid TumorsTerminatedNCT03444701Phase 1
- Phase 1 Study of E7090 in Subjects With Solid TumorCompletedNCT02275910Phase 1
- A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's DiseaseActive, not recruitingNCT07723950
Sponsor listed in the registry: Eisai Inc.
- Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory EpilepsiesNo longer availableNCT04457687
Sponsor listed in the registry: Eisai Inc.
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Phase 1/2
Sponsor listed in the registry: Eisai Inc.
- A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorActive, not recruitingNCT04078295Phase 1/2
- A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseActive, not recruitingNCT03887455Phase 3
Sponsor listed in the registry: Eisai Inc.
- Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)Active, not recruitingNCT07849660
Sponsor listed in the registry: Eisai Inc.
- Study of E7389 Liposomal Formulation in Participants With Solid TumorActive, not recruitingNCT03207672Phase 1
- A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast CancerActive, not recruitingNCT04288089Phase 1
Sponsor listed in the registry: Eisai Inc.
- A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male ParticipantsCompletedNCT07308236Phase 1
Sponsor listed in the registry: Eisai Inc.
- A Study of Oral E1018 in Healthy Adult ParticipantsActive, not recruitingNCT06854042Phase 1
Sponsor listed in the registry: Eisai Inc.
- A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCompletedNCT04572295Phase 1
- A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood EpilepsyActive, not recruitingNCT04015141Phase 2
Sponsor listed in the registry: Eisai Inc.
- A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical PracticeActive, not recruitingNCT06964113Phase 4
Sponsor listed in the registry: Eisai Korea Inc.
- Study of E7386 in Participants With Selected Advanced NeoplasmsActive, not recruitingNCT03264664Phase 1
Sponsor listed in the registry: Eisai Inc.
- AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidActive, not recruitingNCT04468659Phase 3
Sponsor listed in the registry: Eisai Inc.
- A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast CancerCompletedNCT06188559Phase 2
Sponsor listed in the registry: Eisai Inc.
- A Study of Filgotinib in Korean Participants With Rheumatoid ArthritisCompletedNCT06625242Phase 4
Sponsor listed in the registry: Eisai Korea Inc.
- Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])CompletedNCT03517449Phase 3
Sponsor listed in the registry: Eisai Inc.
- A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid CancerCompletedNCT03573960Phase 4
Sponsor listed in the registry: Eisai Pharmaceuticals India Pvt. Ltd
- A Community-Based Screening Program to Identify Participants at High Risk for Amyloid PathologyActive, not recruitingNCT06043700
Sponsor listed in the registry: Eisai Limited
- A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseaseCompletedNCT01767311Phase 2
Sponsor listed in the registry: Eisai Inc.
- A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene FusionCompletedNCT04238715Phase 2
- A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)Active, not recruitingNCT03833700Phase 1
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingNCT02811861Phase 3
Sponsor listed in the registry: Eisai Inc.
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseActive, not recruitingNCT06602258Phase 2
Sponsor listed in the registry: Eisai Inc.
- A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in JapanActive, not recruitingNCT05228158
- A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsCompletedNCT05091346Phase 1/2
Sponsor listed in the registry: Eisai Inc.
- Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedNCT04568902Phase 1
- A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet SyndromeTerminatedNCT04572243Phase 3
Sponsor listed in the registry: Eisai Inc.
- An Extended Access Program (EAP) for PerampanelNo longer availableNCT02307578
Sponsor listed in the registry: Eisai Inc.
- A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With GoutCompletedNCT05007392Phase 3
- A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia DisorderCompletedNCT05594589Phase 2